<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS103747</article-id>
<article-id pub-id-type="doi">10.1101/2020.11.04.361154</article-id>
<article-id pub-id-type="archive">PPR234513</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>de Vries</surname>
<given-names>Rory D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Schmitz</surname>
<given-names>Katharina S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Bovier</surname>
<given-names>Francesca T.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Noack</surname>
<given-names>Danny</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haagmans</surname>
<given-names>Bart L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Biswas</surname>
<given-names>Sudipta</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rockx</surname>
<given-names>Barry</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gellman</surname>
<given-names>Samuel H.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alabi</surname>
<given-names>Christopher A.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Swart</surname>
<given-names>Rik L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moscona</surname>
<given-names>Anne</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Porotto</surname>
<given-names>Matteo</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department Viroscience, Erasmus MC, Rotterdam, the Netherlands</aff>
<aff id="A2">
<label>2</label>Department of Pediatrics, Columbia University Medical Center, New York, NY, USA</aff>
<aff id="A3">
<label>3</label>Center for Host–Pathogen Interaction, Columbia University Medical Center, New York, NY, USA</aff>
<aff id="A4">
<label>4</label>Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy</aff>
<aff id="A5">
<label>5</label>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA</aff>
<aff id="A6">
<label>6</label>Department of Chemistry, University of Wisconsin, Madison, WI, USA</aff>
<aff id="A7">
<label>7</label>Department of Microbiology &amp; Immunology, Columbia University Medical Center, New York, NY, USA</aff>
<aff id="A8">
<label>8</label>Department of Physiology &amp; Cellular Biophysics, Columbia University Medical Center, New York, NY, USA</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding authors Contacts details: - Christopher A. Alabi: <email>caa238@cornell.edu</email>, - Rik L. de Swart: <email>r.deswart@erasmusmc.nl</email> - Anne Moscona: <email>am939@cumc.columbia.edu</email> - Matteo Porotto: <email>mp3509@cumc.columbia.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>10</day>
<month>11</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>05</day>
<month>11</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Containment of the COVID-19 pandemic requires reducing viral transmission. SARS-CoV-2 infection is initiated by membrane fusion between the viral and host cell membranes, mediated by the viral spike protein. We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets. Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co-housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals. These lipopeptides are highly stable and non-toxic and thus readily translate into a safe and effective intranasal prophylactic approach to reduce transmission of SARS-CoV-2.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P2">Infection by SARS-CoV-2 requires membrane fusion between the viral envelope and the host cell membrane, at either the cell surface or the endosomal membrane. The fusion process is mediated by the viral envelope spike glycoprotein, S. Upon viral attachment or uptake, host factors trigger large-scale conformational rearrangements in S, including a refolding step that leads directly to membrane fusion and viral entry (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R6">6</xref>). Peptides corresponding to the highly conserved heptad repeat (HR) domain at the C-terminus of the S protein (HRC peptides) may prevent this refolding and inhibit fusion, thereby preventing infection (<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R12">12</xref>) (<xref ref-type="fig" rid="F1">Fig. 1a-c</xref>). The HRC peptides form six-helix bundle (6HB)-like assemblies with the extended intermediate form of the S protein trimer, thereby disrupting the structural rearrangement of S that drives membrane fusion (<xref ref-type="bibr" rid="R7">7</xref>).</p>
<p id="P3">We have previously demonstrated that lipid conjugation of HRC-derived inhibitory peptides markedly increases antiviral potency and <italic>in vivo</italic> half-life (<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R16">16</xref>), and used this strategy to create entry inhibitors for prophylaxis and/or treatment of human parainfluenza virus type 3, measles virus, and Nipah virus infection (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R20">20</xref>). Both dimerization and peptide integration into cell membranes proved key to ensure respiratory tract protection and prevent systemic lipopeptide dissemination (<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R18">18</xref>). The lipid-conjugated peptides administered intranasally to animals reached high concentrations both in the upper and lower respiratory tract, and the specific nature of the lipid can be designed to modulate the extent of transit from the lung to the systemic circulation and organs (<xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R22">22</xref>). Lipid conjugation also enabled activity against viruses that do not fuse until they have been taken up via endocytosis (<xref ref-type="bibr" rid="R23">23</xref>). Here, we show that a dimeric form of a SARS-CoV-2 S-specific lipopeptide is a potent inhibitor of fusion mediated by the SARS-CoV-2 S protein, prevents viral entry, and, when administered intranasally, completely prevents direct-contact transmission of SARS-CoV-2 in ferrets. We propose this compound as a candidate antiviral, to be administered by inhalation or intranasal spray, for pre-exposure or early post-exposure prophylaxis for SARS-CoV-2 transmission in humans.</p>
<p id="P4">To improve the antiviral potency of the previously assessed SARS-CoV-2 HRC-lipopeptide fusion inhibitor (<xref ref-type="bibr" rid="R7">7</xref>), we compared monomeric and dimeric derivatives of the SARS-CoV-2 S-derived HRC-peptide (<xref ref-type="fig" rid="F1">Fig. 1d</xref>). Initial functional evaluation of the SARS-CoV-2 HRC lipopeptides was conducted with a cell-cell fusion assay based on β-galactosidase (β-gal) complementation that we adapted for assessment of SARS-CoV-2 S-mediated fusion. For this assay, cells expressing human angiotensin-converting enzyme 2 (hACE2) and the N-terminal fragment of β-gal were mixed with cells expressing the SARS-CoV-2 S protein and the C-terminal fragment of β-gal. When fusion mediated by S occurs, the two fragments of β-gal combine to generate a catalytically active species, and fusion is detected via the luminescence that results from substrate processing by β-gal. This assay format allows the assessment of potential SARS-CoV-2 S-mediated membrane fusion inhibitors without the use of infectious virus. The assay measures an inhibitor’s ability to block fusion of S-bearing cells with receptor-bearing target cells and is predictive of <italic>in vivo</italic> antiviral activity (<xref ref-type="bibr" rid="R14">14</xref>).</p>
<p id="P5">
<xref ref-type="fig" rid="F1">Fig. 1d</xref> shows the antiviral potency of two monomeric and two dimeric SARS-CoV-2 S-derived 36-amino acid (<xref ref-type="fig" rid="F1">Fig. 1b</xref>) HRC-peptides, without (SARS<sub>HRC</sub> and [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>) or with (SARS<sub>HRC</sub>-PEG<sub>4</sub>-chol and [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol) appended cholesterol, in cell-cell fusion assays. The percentage inhibition corresponds to the extent of luminescence signal suppression observed in the absence of any inhibitor (<italic>i</italic>.<italic>e</italic>., 0% inhibition corresponds to maximum luminescence signal). Dimerization increased the peptide potency (see SARS<sub>HRC</sub> <italic>vs</italic>. [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub> in <xref ref-type="fig" rid="F1">Fig. 1d</xref>). The dimeric form of HRC lipopeptide was also more potent than its monomeric lipopeptide counterpart (SARS<sub>HRC</sub>-PEG<sub>4</sub>-chol IC<sub>50</sub> ~10 nM and [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol IC<sub>50</sub>~3nM, (Two-way ANOVA, <italic>p</italic>&lt;0.0001)). This dimeric cholesterol-conjugated peptide ([SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol; red line in <xref ref-type="fig" rid="F1">Fig. 1d</xref>) is the most potent lipopeptide against SARS-CoV-2 that has been identified thus far. A lipopeptide based on the human parainfluenza virus type 3 (HPIV3) F protein HRC domain, used as a negative control, did not inhibit fusion at any concentration tested (<xref ref-type="supplementary-material" rid="SD1">Fig. S1</xref>). A cellular toxicity (MTT) assay was performed in parallel with this experiment to evaluate the potential toxicity of each lipopeptide (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>). Toxicity for each of the lipopeptides in this assay was minimal, even at the highest concentrations tested (&lt;20% at 100 μM). No toxicity was observed for the dimeric SARS-CoV-2 lipopeptide at its IC<sub>90</sub> entry inhibitory concentration (~350 nM).</p>
<p id="P6">Despite the overall stability of the SARS-CoV-2 genome, variants with mutations in S have spread globally (<xref ref-type="bibr" rid="R24">24</xref>–<xref ref-type="bibr" rid="R32">32</xref>). These mutations in S altered infectivity of cells (<italic>e</italic>.<italic>g</italic>., D614G (<xref ref-type="bibr" rid="R24">24</xref>)) or were located in the putative target domain of the HRC peptide (<italic>e</italic>.<italic>g</italic>., S943P). To determine the potency of the [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide for a range of variant SARS-CoV-2 viruses, we examined fusion inhibition mediated by each of these emerging S protein mutants. In addition, to assess the potential for broad-spectrum activity we assessed potency against the S of SARS-CoV and MERS-CoV (using dipeptidyl peptidase 4 (DPP4) receptor-bearing cells as the target for the latter). <xref ref-type="fig" rid="F1">Fig. 1e</xref> shows the IC<sub>50</sub> and IC<sub>90</sub> of [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol for inhibition of fusion by the S mutants and in addition, for SARS-CoV S and MERS-CoV S. The [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol lipopeptide inhibited all SARS-CoV-2 strains with S mutations at comparable potency and showed considerable potency against both SARS-CoV and MERS-CoV.</p>
<p id="P7">The lead peptide, [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol, was subsequently assessed for its ability to block entry of live SARS-CoV-2 in VeroE6 and VeroE6 cells overexpressing the protease TMPRSS2 (<xref ref-type="bibr" rid="R33">33</xref>), one of the host factors thought to facilitate viral entry at the cell membrane (<xref ref-type="bibr" rid="R2">2</xref>). The TMPRSS2-expressing cells accurately represent the entry route in airway cells, an important feature highlighted by the failure of chloroquine to inhibit infection in TMPRSS2-expressing Vero cells and in human lung cells (<xref ref-type="bibr" rid="R34">34</xref>). The [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide was dissolved in an aqueous buffer containing 2% dimethylsulfoxide (DMSO), was incubated with cells for 1 hr at 37 °C, after which a fixed concentration of SARS-CoV-2 was added. After 8 hrs at 37 °C, fusion events were quantified by SARS-CoV-2 nucleoprotein (NP) staining. The [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide inhibited live virus entry with an IC<sub>50</sub> ~300 nM in cells not overexpressing TMPRSS and ~5 nM in VeroE6-TMPRSS2, with an IC<sub>90</sub> ~1 uM in both cell types (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). In addition, we assessed the efficacy of the [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide dissolved in a sucrose solution instead of DMSO, which would strengthen translational potential for human use. [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide retained its potency in this formulation, with an IC<sub>50</sub> ~300 nM in cells not overexpressing TMPRSS2 and ~5 nM in VeroE6-TMPRSS2 (<xref ref-type="fig" rid="F2">Fig. 2b</xref>). The efficacy data are summarized in <xref ref-type="fig" rid="F2">Fig. 2c</xref>.</p>
<p id="P8">Ferrets are an ideal model for assessing respiratory virus transmission, either by direct contact or by aerosol transmission (<xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R40">40</xref>). Mustelids are highly susceptible to infection with SARS-CoV-2, as also illustrated by frequent COVID-19 outbreaks at mink farms (<xref ref-type="bibr" rid="R41">41</xref>). Direct contact transmission of SARS-CoV in ferrets was demonstrated in 2003 (<xref ref-type="bibr" rid="R42">42</xref>), and both direct contact and airborne transmission have recently been shown in ferrets for SARS-CoV-2 (<xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R44">44</xref>). Direct contact transmission in the ferret model is highly reproducible (100% transmission from donor to acceptor animals), but ferrets display limited clinical signs. After infection via direct inoculation or transmission, SARS-CoV-2 can readily be detected in and isolated from the throat and nose, and viral replication leads to seroconversion.</p>
<p id="P9">To assess the efficacy of [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol in preventing SARS-CoV-2 transmission, naive ferrets were treated prophylactically with the lipopeptide before being co-housed with SARS-CoV-2 infected ferrets. In this setup, transmission via multiple routes can theoretically occur (aerosol, orofecal, and scratching or biting during play or fight), and ferrets are continuously exposed to infectious virus during the period of co-housing, providing a stringent test for antiviral efficacy. The study design is shown in <xref ref-type="fig" rid="F3">Fig. 3a</xref>. Three donor ferrets (grey in diagram) were inoculated intranasally with 5.4 × 10<sup>5</sup> TCID<sub>50</sub> SARS-CoV-2 on day 0. Twelve recipient ferrets housed separately were treated by nose drops with a mock preparation (red) or [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide (green) on 1- and 2-days post-inoculation (DPI) of the donor animals. The [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptides for intranasal administration were dissolved to a concentration of 6 mg/mL in an aqueous buffer containing 2% DMSO, administering a final dose of 2.7 mg/kg to ferrets (450 uL, equally divided over both nostrils). Six hours after the second treatment on 2 DPI, one infected donor ferret was co-housed with four naive recipient ferrets (two mock-treated, two peptide-treated). The experiment was performed in three separate, negatively pressurized HEPA-filtered ABSL3-isolator cages. After a 24-hour transmission period, co-housing was stopped and donor, mock-treated and peptide-treated ferrets were housed as separate groups. Additional [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide treatments were given to recipient animals on 3 and 4 DPI. Peptide stocks and working dilutions had similar IC<sub>50</sub> s, confirming that peptide-treated ferrets were always dosed with comparable amounts (<xref ref-type="supplementary-material" rid="SD1">Fig. S3a and 3b</xref>).</p>
<p id="P10">Throat and nose swabs were collected from ferrets daily for the first week, and additionally on 14 and 21 DPI, for assessment of viral replication. Small volume blood samples were collected on 0, 7, 14, and 21 DPI for assessing the presence of neutralizing antibodies in serum. <xref ref-type="fig" rid="F3">Fig. 3b and 3c</xref> shows the viral loads (detection of viral genomes via RT-qPCR) for directly inoculated donor animals (grey), mock-treated recipient animals (red) and lipopeptide-treated recipient animals (green). All directly inoculated donor ferrets were productively infected, as shown by SARS-CoV-2 genome detection in throat and nose swabs, and efficiently and reproducibly transmitted the virus to all mock-treated acceptor ferrets (<xref ref-type="fig" rid="F3">Fig. 3b and 3c</xref>, red curves). Notably, productive SARS-CoV-2 infection was not detected in the throat or nose of any of the peptide-treated recipient animals (<xref ref-type="fig" rid="F3">Fig. 3b and 3c</xref>, green curves). A slight rise in viral loads in samples collected at 3DPI was detected, at the end of the co-housing, confirming that peptide-treated animals were exposed to SARS-CoV-2. Strikingly, from 4 DPI onwards, there was a clear treatment effect in which the [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide protected 6/6 ferrets from transmission and productive infection. Donor ferrets and 6/6 mock-treated recipient animals seroconverted on 21 DPI.</p>
<p id="P11">None of the peptide-treated animals seroconverted, demonstrating that in-host virus replication was completely blocked by [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol<italic>)</italic> (<xref ref-type="fig" rid="F4">Fig. 4</xref>). None of the animals showed clinical signs as a result of infection or treatment over the course of the experiment, and body weights remained stable (<xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>).</p>
<p id="P12">Based on the <italic>in vitro</italic> and <italic>in vivo</italic> results shown here, we expect that prophylactic intranasal administration of the [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide prevents transmission from infected to uninfected individuals, even during a 24-hour period of intense direct contact. <italic>In vitro</italic> data suggest that this lipopeptide will be effective against emerging variants with mutations in S and possibly against other coronaviruses. This efficacy can be readily assessed in real time and adjustments made if needed.</p>
<p id="P13">Parallel approaches to prevent transmission that target ACE2 or the interaction between S and ACE2 have also shown promise <italic>in vitro</italic> (e.g. the “miniprotein” approach recently reported by Cao <italic>et al</italic> (<xref ref-type="bibr" rid="R45">45</xref>)). In distinction to various antibody or nanobody products (<xref ref-type="bibr" rid="R46">46</xref>) the [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide is inexpensive to produce, has a long shelf life, and does not require refrigeration. Moreover, this is the first compound to convincingly prevent SARS-CoV-2 transmission in a relevant animal model. We envision the use of fusion inhibitory lipopeptides as complementary to other pandemic mitigation strategies. In addition to the nasal drop administration for the [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide, other routes that would be equally or more acceptable to humans, for example inhalation devices, are being explored. This HRC lipopeptide fusion inhibitor is feasible for advancement to human use and should readily translate into a safe and effective nasal spray or inhalation administered fusion inhibitor for anti-SARS-CoV-2 prophylaxis, thus supporting containment of the current COVID-19 pandemic.</p>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS103747-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66448" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S1">
<title>Acknowledgements</title>
<p>We thank Mart Lamers, Sander Herfst, Elwin Verveer, Anna Mykytyn and Marion Koopmans for their contributions to this study.</p>
<sec id="S2">
<title>Funding</title>
<p>This work was supported by funding from the National Institutes of Health (AI146980, AI121349, and NS091263 to MP, AI114736 to AM), the Sharon Golub Fund at Columbia University Medical Center, and a Harrington Discovery Institute COVID-19 Award to AM.</p>
</sec>
</ack>
<sec id="S3" sec-type="data-availability">
<title>Data and materials availability</title>
<p id="P14">All data is available in the manuscript or the supplementary materials.</p>
</sec>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P15">
<bold>Author contributions:</bold> conceptualization RDdV, SHG, CAA, RLdS, AM, MP; formal analysis RDdV, FTB, CAA, KSS, MP; funding acquisition BLH, RLdS, AM, MP; investigation RDdV, FTB, KSS, DN, SHG, CAA, RLdS, MP; resources BLH, BR, CAA, RLdS, AM, MP; supervision RLdS, CAA, AM, MP; visualization RDdV, KS, AM, MP; writing – original draft RDdV. RLdS, AM, MP; final version: all coauthors provided feedback to the final draft.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P16">
<bold>Competing interest:</bold> RDdV, FTB, RLdS, AM and MP are listed as inventors on a provisional patent application covering findings reported in this manuscript.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Structure, Function, and Evolution of Coronavirus Spike Proteins</article-title>
<source>Annu Rev Virol</source>
<year>2016</year>
<volume>3</volume>
<fpage>237</fpage>
<lpage>261</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baric</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus</article-title>
<source>J Virol</source>
<year>2020</year>
<volume>94</volume>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source>Nature</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosch</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>van der Zee</surname>
<given-names>R</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Rottier</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex</article-title>
<source>J Virol</source>
<year>2003</year>
<volume>77</volume>
<fpage>8801</fpage>
<lpage>8811</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2017</year>
<volume>114</volume>
<fpage>11157</fpage>
<lpage>11162</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Outlaw</surname>
<given-names>VK</given-names>
</name>
<etal/>
</person-group>
<article-title>Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain</article-title>
<source>mBio</source>
<year>2020</year>
<volume>11</volume>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>[Development of peptidic MERS-CoV entry inhibitors]</article-title>
<source>Yao Xue Xue Bao</source>
<year>2015</year>
<volume>50</volume>
<fpage>1513</fpage>
<lpage>1519</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike</article-title>
<source>Sci Adv</source>
<year>2019</year>
<volume>5</volume>
<comment>eaav4580</comment>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title>
<source>Cell Res</source>
<year>2020</year>
<volume>30</volume>
<fpage>343</fpage>
<lpage>355</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity</article-title>
<source>J Virol</source>
<year>2020</year>
<volume>94</volume>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases</article-title>
<source>Int J Mol Sci</source>
<year>2020</year>
<volume>21</volume>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porotto</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Viral entry inhibitors targeted to the membrane site of action</article-title>
<source>J Virol</source>
<year>2010</year>
<volume>84</volume>
<fpage>6760</fpage>
<lpage>6768</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porotto</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry</article-title>
<source>PLoS Pathog</source>
<year>2010</year>
<volume>6</volume>
<fpage>e1001168</fpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pessi</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity</article-title>
<source>PLoS One</source>
<year>2012</year>
<volume>7</volume>
<fpage>e36833</fpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Welsch</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group>
<article-title>Fatal measles virus infection prevented by brain-penetrant fusion inhibitors</article-title>
<source>J Virol</source>
<year>2013</year>
<volume>87</volume>
<fpage>13785</fpage>
<lpage>13794</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Outlaw</surname>
<given-names>VK</given-names>
</name>
<etal/>
</person-group>
<article-title>Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent</article-title>
<source>J Am Chem Soc</source>
<year>2019</year>
<volume>141</volume>
<fpage>12648</fpage>
<lpage>12656</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueira</surname>
<given-names>TN</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles</article-title>
<source>ACS Nano</source>
<year>2018</year>
<volume>12</volume>
<fpage>9855</fpage>
<lpage>9865</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueira</surname>
<given-names>TN</given-names>
</name>
<etal/>
</person-group>
<article-title>Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane</article-title>
<source>Bioconjug Chem</source>
<year>2018</year>
<volume>29</volume>
<fpage>3362</fpage>
<lpage>3376</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathieu</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides</article-title>
<source>Sci Rep</source>
<year>2017</year>
<volume>7</volume>
<fpage>43610</fpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueira</surname>
<given-names>TN</given-names>
</name>
<etal/>
</person-group>
<article-title>In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence</article-title>
<source>J Virol</source>
<year>2017</year>
<volume>91</volume>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Figueira</surname>
<given-names>TN</given-names>
</name>
<etal/>
</person-group>
<article-title>Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance</article-title>
<source>Sci Rep</source>
<year>2017</year>
<volume>7</volume>
<fpage>45647</fpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>KK</given-names>
</name>
<etal/>
</person-group>
<article-title>Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus</article-title>
<source>J Biol Chem</source>
<year>2011</year>
<volume>286</volume>
<fpage>42141</fpage>
<lpage>42149</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daniloski</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sanjana</surname>
<given-names>NE</given-names>
</name>
</person-group>
<article-title>The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>YN</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East</article-title>
<source>Emerg Microbes Infect</source>
<year>2020</year>
<fpage>137</fpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maitra</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility</article-title>
<source>J Biosci</source>
<year>2020</year>
<volume>45</volume>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karacan</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>
<article-title>The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey</article-title>
<source>North Clin Istanb</source>
<year>2020</year>
<volume>7</volume>
<fpage>203</fpage>
<lpage>209</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biswas</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Majumder</surname>
<given-names>PP</given-names>
</name>
</person-group>
<article-title>Analysis of RNA sequences of 3636 SARS-CoV-2 collected from 55 countries reveals selective sweep of one virus type</article-title>
<source>Indian J Med Res</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eaaswarkhanth</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Madhoun</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Al-Mulla</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?</article-title>
<source>Int J Infect Dis</source>
<year>2020</year>
<volume>96</volume>
<fpage>459</fpage>
<lpage>460</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>HC</given-names>
</name>
</person-group>
<article-title>A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity?</article-title>
<source>Vaccines (Basel)</source>
<year>2020</year>
<volume>8</volume>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Weeraratne</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Snowdon</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Parida</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment</article-title>
<source>Pathogens</source>
<year>2020</year>
<volume>9</volume>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mykytyn</surname>
<given-names>AZ</given-names>
</name>
<etal/>
</person-group>
<article-title>The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells</article-title>
<source>bioRxiv</source>
<year>2020</year>
<comment>2020.2009.2007.286120</comment>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>585</volume>
<fpage>588</fpage>
<lpage>590</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munoz-Fontela</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Animal models for COVID-19</article-title>
<source>Nature</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richard</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 is transmitted via contact and via the air between ferrets</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>3496</fpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munster</surname>
<given-names>VJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Practical considerations for high-throughput influenza A virus surveillance studies of wild birds by use of molecular diagnostic tests</article-title>
<source>J Clin Microbiol</source>
<year>2009</year>
<volume>47</volume>
<fpage>666</fpage>
<lpage>673</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munster</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Avian influenza virus: of virus and bird ecology</article-title>
<source>Vaccine</source>
<year>2009</year>
<volume>27</volume>
<fpage>6340</fpage>
<lpage>6344</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herfst</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Airborne transmission of influenza A/H5N1 virus between ferrets</article-title>
<source>Science</source>
<year>2012</year>
<volume>336</volume>
<fpage>1534</fpage>
<lpage>1541</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>
<article-title>Delineating morbillivirus entry, dissemination and airborne transmission by studying in vivo competition of multicolor canine distemper viruses in ferrets</article-title>
<source>PLoS Pathog</source>
<year>2017</year>
<volume>13</volume>
<fpage>e1006371</fpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molenaar</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison)</article-title>
<source>Vet Pathol</source>
<year>2020</year>
<volume>57</volume>
<fpage>653</fpage>
<lpage>657</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martina</surname>
<given-names>BE</given-names>
</name>
<etal/>
</person-group>
<article-title>Virology: SARS virus infection of cats and ferrets</article-title>
<source>Nature</source>
<year>2003</year>
<volume>425</volume>
<fpage>915</fpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets</article-title>
<source>MBio</source>
<year>2020</year>
<volume>11</volume>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YI</given-names>
</name>
<etal/>
</person-group>
<article-title>Infection and Rapid Transmission of SARS-CoV-2 in Ferrets</article-title>
<source>Cell Host Microbe</source>
<year>2020</year>
<volume>27</volume>
<fpage>704</fpage>
<lpage>709</lpage>
<comment>e702</comment>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>De novo design of picomolar SARS-CoV-2 miniprotein inhibitors</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>426</fpage>
<lpage>431</lpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoof</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<boxed-text id="BX1" position="float" orientation="portrait">
<caption>
<title>One-sentence summary</title>
</caption>
<p>A dimeric form of a SARS-CoV-2-derived lipopeptide is a potent inhibitor of fusion and infection <italic>in vitro</italic> and transmission <italic>in vivo</italic>.</p>
</boxed-text>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Peptide-lipid conjugates that inhibit SARS-CoV-2 spike (S)-mediated fusion.</title>
<p>(A) The functional domains of SARS-CoV-2 S protein: receptor-binding domain (RBD) and heptad repeats (HRN and HRC) are indicated. (B) Sequence of the peptides that derive from the HRC domain of SARS-CoV-2 S. (C) Monomeric and dimeric forms of lipid tagged SARS-CoV-2 inhibitory peptides that were assessed in cell-cell fusion assays. (D) Cell-cell fusion assays with different inhibitory peptides. The percentage inhibition is shown for four different peptides used at increasing concentrations. Inhibitory concentrations 50% and 90% were calculated (dotted lines). Percent inhibition was calculated as the ratio of relative luminescence units in the presence of a specific concentration of inhibitor and the relative luminescence units in the absence of inhibitor and corrected for background luminescence. Data are means ± standard deviation (SD) from three separate experiments. The difference between the results for [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol and SARS<sub>HRC</sub>-PEG<sub>4</sub>-chol lipopeptides are significant (Two-way ANOVA, <bold>**** p&lt;0.0001</bold>). (E) Fusion inhibitory activity of [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol peptide against SARS-CoV-2 S variants, MERS-CoV-2 S, and SARS-CoV S. Data are means ± standard deviation (SD) from three separate experiments.</p>
</caption>
<graphic xlink:href="EMS103747-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Inhibition of live SARS-CoV-2 entry by [SARS-CoV-2-HRC-peg<sub>4</sub>]<sub>2</sub>-chol peptide.</title>
<p>The percentage inhibition of infection is shown on VeroE6 and VeroE6-TMPRSS2 cells with increasing concentrations of [SARS-CoV-2-HRC-peg<sub>4</sub>]<sub>2</sub>-chol. A DMSO-diluted stock (A, as used in ferrets) and sucrose-diluted stock (B, potential formulation for human use) were tested side-by-side. Inhibitory concentrations 50% and 90% were calculated (dotted lines). (C) Inhibitory concentrations 50% and 90% of [SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol in live SARS-CoV-2 viral infection assays in VeroE6 cells with or without TMPRSS2 protease overexpression.</p>
</caption>
<graphic xlink:href="EMS103747-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>[SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol prevents SARS-CoV-2 transmission <italic>in vivo</italic>.</title>
<p>(a) Experimental design. (b) Viral loads detected in throat and nose swabs via RT-PCR. Viral loads are displayed as 40-Ct. Donor animals shown in grey, mock-treated animals in red, peptide-treated animals in green. 3/3 donor animals, 6/6 mock-treated animals and 0/6 lipopeptide-treated animals were productively infected. Symbols correspond to individual animals and are consistent throughout figures.</p>
</caption>
<graphic xlink:href="EMS103747-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>[SARS<sub>HRC</sub>-PEG<sub>4</sub>]<sub>2</sub>-chol-treated animals do not seroconvert.</title>
<p>Presence of neutralizing antibodies was determined in a live virus neutralization assay. Virus neutralizing antibodies are displayed as endpoint serum dilution factor to block SARS-CoV-2 replication. Donor animals shown in grey, mock-treated animals in red, peptide-treated animals in green. 3/3 donor animals, 6/6 mock-treated animals and 0/6 lipopeptide-treated animals seroconverted. Symbols correspond to individual animals and are consistent throughout figures.</p>
</caption>
<graphic xlink:href="EMS103747-f004"/>
</fig>
</floats-group>
</article>
